Rhumbline Advisers Sarepta Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 270,941 shares of SRPT stock, worth $33.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
270,941
Previous 109,999
146.31%
Holding current value
$33.8 Million
Previous $14.2 Million
200.62%
% of portfolio
0.04%
Previous 0.01%
Shares
28 transactions
Others Institutions Holding SRPT
# of Institutions
561Shares Held
85.5MCall Options Held
3.67MPut Options Held
1.75M-
Black Rock Inc. New York, NY10.3MShares$1.29 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.13 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$540 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$517 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$477 Million0.33% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $10.9B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...